Drugs / Amphotericine B
Amphotericine B
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00391014 | Jan 2006 → Dec 2008 | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | PETHEMA Foundation | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04839653 | May 2021 → Apr 2022 | acute respiratory distress syndrome, bacterial infectious disease, infectious disease with sepsis, pneumonia | MEDSI Clinical Hospital 1, ICU | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2000-11-17 | Gilead Sciences | Study Results Published in Journal of Clinical Infectious Diseases Demonstrate That Ambisome® Has an Improved Safety Profile Compared to Abelcet® gilead.com ↗ |
| 1999-09-27 | Gilead Sciences | AmBisome® Phase III Study For Cryptococcal Meningitis gilead.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amphotericine B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00391014 ↗ |
| Known as | Ambisome | “The Nebulized Liposomal Amphotericin B (Ambisome) prophylaxis against IPA has shown good tolerance, safety and efficacy in lung transplant recipients.” NCT00391014 ↗ |
| Known as | Liposomal Amphotericin B | “The Nebulized Liposomal Amphotericin B (Ambisome) prophylaxis against IPA has shown good tolerance, safety and efficacy in lung transplant recipients.” NCT00391014 ↗ |